慢性阻塞性肺疾病是一种慢性气道炎症性疾病。我们前期临床数据显示，COPD患者经华盖平喘方治疗后，肺功能改善，细胞免疫水平提高。前期研究发现，JNK水平在慢性阻塞性肺疾病大鼠中表达上升，并且预测出JNK的上游lncRNAZNF674-AS1，且lncRNAZNF674-AS1水平在慢性阻塞性肺疾病大鼠中表达下调。本研究拟建立COPD痰热阻肺证病证结合模型并用华盖平喘方干预，结合功能获得性（过表达慢病毒）和功能缺失性（敲减慢病毒）实验，在动物和细胞水平，验证华盖平喘方通过lncRNAZNF674-AS1/JNK调控慢性阻塞性肺疾病痰热阻肺证气道炎症。本研究将从中西医病证结合角度，为中药复方治疗COPD痰热阻肺证提供实验依据。

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the airways.In the previous study, clinical data showed lung function and cellular immunity advanced in COPD patients after hua gai ping chuan prescription treatment.We also found that JNK appeared to be advanced in COPD rats,and lncRNAZNF674-AS1 reduced in COPD rats. The research will establish COPD heat and phlegm blocking lung syndrome models and prevent this disease by hua gai ping chuan prescription.We designed function acquired experiment (virus overexpression)and function deficiency experiment(shRNA).In animal and cell level,we confirmed hua gai ping chuan prescription can regulate airway inflammation of heat and phlegm blocking lung syndrome in COPD.This study may provide evidence of Chinese medicine compound treating heat and phlegm blocking lung syndrome in COPD,in view of integrative medicine of traditional Chinese medicine.